LPAR1 and ovarian carcinoma: We have asked [1] the extent of fibrosis as a result of metastatic colonization in metastatic colonization in model systems; [2] the effect of orally available LPA1 antagonists on metastasis and fibrosis in triple-negative breast cancer model systems; [3] given the association of LPA receptors and ovarian cancer progression [25–27], the effect of these antagonists in ovarian cancer metastasis, and [4] the effect of recently FDA approved drugs for idiopathic pulmonary fibrosis, pirfenidone [28] and nintedanib [29], in a breast cancer model system.